Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : Online availability of Sanofi's half-year financial report for 2021

07/29/2021 | 12:25pm EDT

Online availability of Sanofi’s half-year financial report for 2021


PARIS – July 29, 2021 - Sanofi announces that its half-year financial report for the period ending June 30, 2021 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

This document may be found on the company’s corporate website: www.sanofi.com and downloaded from the “Investors” page, under the heading “Regulated Information in France”.

About Sanofi 

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. 

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. 

Media Relations Contacts  
Ashleigh Koss
Tel: +1 (908) 205-2572
Ashleigh.Koss@sanofi.com

Sandrine Guendoul
Tel.: +33 (0)6 25 09 14 25
MR@sanofi.com

Nicolas Kressmann
Tel.: +1 (732) 532-5318
Nicolas.Kressmann@sanofi.com

Investor Relations Contacts Paris 
Eva Schaefer-Jansen 
Arnaud Delepine 
Nathalie Pham 

Investor Relations Contacts North America 
Felix Lauscher 
Fara Berkowitz 
Suzanne Greco  

Tel.: +33 (0)1 53 77 45 45  
investor.relations@sanofi.com 
https://www.sanofi.com/en/investors/contact 

Attachment


All news about SANOFI
10:40aSANOFI : SVB Leerink Upgrades Sanofi to Outperform from Market Perform
MT
07:47aSANOFI : - Availability of the Q3 2021 Memorandum for modelling purposes
AQ
01:22aSANOFI : New research presented at IDWeek 2021 reinforces Sanofi's robust vaccines pipelin..
PU
01:00aGlobal vaccines project to revamp rules after Britain got more than Botswana
RE
09/24SANOFI : Availability of the Q3 2021 Memorandum for modelling purposes
AQ
09/23SANOFI : New Dupixent« (dupilumab) data in patients as young as 6 years old with moderate-..
PU
09/23VC DAILY : Biotechs Seek New Skill Set From -2-
DJ
09/23SANOFI : Deutsche Bank keeps a Sell rating
MD
09/22PRESS RELEASE : Pfizer and BioNTech Expand -3-
DJ
09/21SANOFI : New Dupixent« (dupilumab) data in patients as young as 6 years old with moderate-..
AQ
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 292 M 43 601 M 43 601 M
Net income 2021 6 046 M 7 068 M 7 068 M
Net Debt 2021 7 878 M 9 211 M 9 211 M
P/E ratio 2021 17,2x
Yield 2021 4,01%
Capitalization 103 B 121 B 121 B
EV / Sales 2021 2,98x
EV / Sales 2022 2,72x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 82,12 €
Average target price 104,78 €
Spread / Average Target 27,6%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI4.35%120 553
JOHNSON & JOHNSON3.68%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY34.09%210 037